172 related articles for article (PubMed ID: 22827244)
21. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
Tambyah PA; Wilder-Smith A; Pavlova BG; Barrett PN; Oh HM; Hui DS; Yuen KY; Fritsch S; Aichinger G; Loew-Baselli A; van der Velden M; Maritsch F; Kistner O; Ehrlich HJ
Vaccine; 2012 Jan; 30(2):329-35. PubMed ID: 22080174
[TBL] [Abstract][Full Text] [Related]
22. Statistical optimization of influenza H1N1 production from batch cultures of suspension Vero cells (sVero).
Paillet C; Forno G; Soldano N; Kratje R; Etcheverrigaray M
Vaccine; 2011 Sep; 29(41):7212-7. PubMed ID: 21756959
[TBL] [Abstract][Full Text] [Related]
23. [Selected problems of manufacturing influenza vaccines].
Augustynowicz E
Przegl Epidemiol; 2010; 64(3):373-80. PubMed ID: 20976949
[TBL] [Abstract][Full Text] [Related]
24. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.
Ehrlich HJ; Müller M; Fritsch S; Zeitlinger M; Berezuk G; Löw-Baselli A; van der Velden MV; Pöllabauer EM; Maritsch F; Pavlova BG; Tambyah PA; Oh HM; Montomoli E; Kistner O; Noel Barrett P
J Infect Dis; 2009 Oct; 200(7):1113-8. PubMed ID: 19712040
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of novel disposable bioreactors on pandemic influenza virus production.
Lai CC; Weng TC; Tseng YF; Chiang JR; Lee MS; Hu AY
PLoS One; 2019; 14(8):e0220803. PubMed ID: 31404117
[TBL] [Abstract][Full Text] [Related]
26. Use of MDCK cells for production of live attenuated influenza vaccine.
Liu J; Shi X; Schwartz R; Kemble G
Vaccine; 2009 Oct; 27(46):6460-3. PubMed ID: 19559113
[TBL] [Abstract][Full Text] [Related]
27. Strategies for developing vaccines against H5N1 influenza A viruses.
Horimoto T; Kawaoka Y
Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a fully human monoclonal antibody against extracellular domain of matrix protein 2 of influenza A virus.
Ozawa T; Jin A; Tajiri K; Takemoto M; Okuda T; Shiraki K; Kishi H; Muraguchi A
Antiviral Res; 2011 Sep; 91(3):283-7. PubMed ID: 21726583
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
Szymczakiewicz-Multanowska A; Groth N; Bugarini R; Lattanzi M; Casula D; Hilbert A; Tsai T; Podda A
J Infect Dis; 2009 Sep; 200(6):841-8. PubMed ID: 19673651
[TBL] [Abstract][Full Text] [Related]
30. Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production.
Minor PD
Clin Infect Dis; 2010 Feb; 50(4):560-5. PubMed ID: 20085485
[TBL] [Abstract][Full Text] [Related]
31. [Safety of cell culture-based influenza vaccines].
Schmitt HJ; Gregersen JP; Trusheim H; Bröker M
Med Monatsschr Pharm; 2010 Jan; 33(1):4-10. PubMed ID: 20131669
[TBL] [Abstract][Full Text] [Related]
32. Vaccines in development against avian influenza.
Cox MM
Minerva Med; 2007 Apr; 98(2):145-53. PubMed ID: 17519856
[TBL] [Abstract][Full Text] [Related]
33. [Influenza vaccine].
Horimoto T; Murakami S; Kawaoka Y
Nihon Rinsho; 2008 Oct; 66(10):2013-8. PubMed ID: 18939506
[TBL] [Abstract][Full Text] [Related]
34. Establishment of Vero cell RNA polymerase I-driven reverse genetics for Influenza A virus and its application for pandemic (H1N1) 2009 influenza virus vaccine production.
Song MS; Baek YH; Pascua PNQ; Kwon HI; Park SJ; Kim EH; Lim GJ; Choi YK
J Gen Virol; 2013 Jun; 94(Pt 6):1230-1235. PubMed ID: 23486669
[TBL] [Abstract][Full Text] [Related]
35. Development and preclinical testing of HNVAC, a cell culture-based H1N1 pandemic influenza vaccine from India.
Hegde NR; Kumar D; Rao PP; Kumari PK; Kaushik Y; Ravikrishnan R; Prasad SD; Ella KM
Vaccine; 2014 Jun; 32(29):3636-43. PubMed ID: 24801052
[TBL] [Abstract][Full Text] [Related]
36. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.
Ehrlich HJ; Müller M; Oh HM; Tambyah PA; Joukhadar C; Montomoli E; Fisher D; Berezuk G; Fritsch S; Löw-Baselli A; Vartian N; Bobrovsky R; Pavlova BG; Pöllabauer EM; Kistner O; Barrett PN;
N Engl J Med; 2008 Jun; 358(24):2573-84. PubMed ID: 18550874
[TBL] [Abstract][Full Text] [Related]
37. Influenza vaccines: the good, the bad, and the eggs.
Schultz-Cherry S; Jones JC
Adv Virus Res; 2010; 77():63-84. PubMed ID: 20951870
[TBL] [Abstract][Full Text] [Related]
38. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective.
Abelin A; Colegate T; Gardner S; Hehme N; Palache A
Vaccine; 2011 Feb; 29(6):1135-8. PubMed ID: 21115061
[TBL] [Abstract][Full Text] [Related]
39. The development of vaccine viruses against pandemic A(H1N1) influenza.
Robertson JS; Nicolson C; Harvey R; Johnson R; Major D; Guilfoyle K; Roseby S; Newman R; Collin R; Wallis C; Engelhardt OG; Wood JM; Le J; Manojkumar R; Pokorny BA; Silverman J; Devis R; Bucher D; Verity E; Agius C; Camuglia S; Ong C; Rockman S; Curtis A; Schoofs P; Zoueva O; Xie H; Li X; Lin Z; Ye Z; Chen LM; O'Neill E; Balish A; Lipatov AS; Guo Z; Isakova I; Davis CT; Rivailler P; Gustin KM; Belser JA; Maines TR; Tumpey TM; Xu X; Katz JM; Klimov A; Cox NJ; Donis RO
Vaccine; 2011 Feb; 29(9):1836-43. PubMed ID: 21199698
[TBL] [Abstract][Full Text] [Related]
40. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.
Pandey A; Singh N; Sambhara S; Mittal SK
Hum Vaccin; 2010 Feb; 6(2):178-88. PubMed ID: 19875936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
